Literature DB >> 21617728

Problems in dealing with very rare adverse effects of new anticancer drugs: the example of trabectedin.

Federica Grosso, Maurizio D'Incalci.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21617728     DOI: 10.1177/030089161109700224

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916


× No keyword cloud information.
  4 in total

1.  A comprehensive safety analysis confirms rhabdomyolysis as an uncommon adverse reaction in patients treated with trabectedin.

Authors:  Federica Grosso; Maurizio D'Incalci; Mirela Cartoafa; Antonio Nieto; Carlos Fernández-Teruel; Vicente Alfaro; Pilar Lardelli; Elena Roy; Javier Gómez; Carmen Kahatt; Arturo Soto-Matos; Ian Judson
Journal:  Cancer Chemother Pharmacol       Date:  2012-04-07       Impact factor: 3.333

2.  Herbal-drug interaction induced rhabdomyolysis in a liposarcoma patient receiving trabectedin.

Authors:  Sabino Strippoli; Vito Lorusso; Anna Albano; Michele Guida
Journal:  BMC Complement Altern Med       Date:  2013-07-30       Impact factor: 3.659

Review 3.  The value of trabectedin in the treatment of soft tissue sarcoma.

Authors:  Tomoki Nakamura; Akihiko Matsumine; Akihiro Sudo
Journal:  Ther Clin Risk Manag       Date:  2016-01-13       Impact factor: 2.423

4.  Severe Rhabdomyolysis during Treatment with Trabectedin in Combination with a Herbal Drug in a Patient with Metastatic Synovial Sarcoma: A Case Report.

Authors:  Angela Damato; Mario Larocca; Ermanno Rondini; Massimo Menga; Carmine Pinto; Annibale Versari
Journal:  Case Rep Oncol       Date:  2017-03-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.